Prescient Therapeutics Limited [ASX:PTX] share price and news 2022

Company Description

Prescient Therapeutics Limited (PTX) is a clinical stage oncology company developing novel compounds that show potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy. The company continues to develop its two drug candidates, PTX-100 and PTX-200, for potential new therapies to treat a range of cancers, including breast and ovarian cancer, as well as leukaemia.

Prescient Therapeutics Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.ptxtherapeutics.com.

This a small cap company with market cap of 64 millions.

Compared to Market and Sector

The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.

Company PE is less than both sector and market. while On the other hand, Company Earning is less than both sector and market.

Earnings PE PB PE growth
Company 0 0 3.52 0
Market 0.85 22.3 1.99 0.84
Sector 1.7 39.6 5.78 0.26

Dividend Growth Chart

The following chart shows you how ptx dividend grows in the recent years.

No data